



Improved Overall Survival¹



Faster and Deeper PSA Response from TITAN's treatment arm¹⁻³ (ERLEADA® + ADT)



Maintenance of Of HRQoL²

Real-world evidence showed that ERLEADA® + ADT has faster and deeper PSA response than enzalutamide + ADT in mCSPC patients³

Reference:

1. Chi KN, et al. AUA 2021. Presentation PD34.

2. Small EJ, et al. Poster presented at ASCO GU Cancers Symposium, San Francisco, USA, 17–19 February 2022. Abstract 73. 3. Lowentritt B, et al. Poster presented at ASCO GU Cancers Symposium, San Francisco, USA, 17–19 February 2022. Abstract 43.

Abbreviations:

PSA: prostate specific antigen, mCSPC: metastatic castration-sensitive prostate cancer, QoL: quality of life, HRQoL: health-related quality of life, RWE: Real-world evidence, ADT: Androgen-depreviation therapy



Scan QR
for Full Prescribing Information



Janssen, A Division of Johnson & Johnson Pte Ltd
2 Science Park Drive, #07-13,
Ascent Tower B, Singapore Science Park 1,
Singapore 118222